One Infusion of Donor Stem Cells Helped Frail Seniors Walk Farther Nine Months Later

The Cocktail Report (sound really smart around your friends):

If you have watched a parent decline into frailty, you know the diagnosis comes with no treatment to slow it. Doctors manage its consequences, but nothing is approved to treat the condition itself.

A new randomized trial is the strongest controlled evidence yet that this can change. The results were published in February in the journal Cell Stem Cell.

Frailty means heightened vulnerability to stressors such as infections, falls, and surgery, and it goes well beyond normal aging. It affects an estimated 12 to 24 percent of adults over 65, and it sharply raises the risk of disability, hospitalization, and death.

The therapy, called laromestrocel, consists of mesenchymal stem cells, the supportive repair cells found in bone marrow, harvested from young healthy donors. Each participant received one intravenous infusion of either a placebo or one of four doses, from 25 million to 200 million cells.

The main measure was the six-minute walk test, which counts how far a person can walk in six minutes and predicts hospitalization and death in older adults. All groups started near 300 meters.

At six months, the highest dose had walked 41 meters farther than placebo, a difference that narrowly missed statistical significance. By nine months, the gap had grown to 63 meters, and the middle dose had reached 49 meters.

A 63-meter gain matters in daily life. That is roughly the walk from a parking space into a store, and doctors typically consider 18 to 32 meters clinically meaningful in comparable populations.

The placebo group declined over the same period, which the authors say may reflect the natural course of frailty. Patient questionnaires showed improvement that correlated with how far people actually walked.

A blood marker called soluble TIE2, a fragment of a receptor that regulates blood vessel health, fell as the dose rose. The authors connect this to inflammaging, the chronic low-grade inflammation that accumulates with age.

Safety held up. A federally appointed monitoring board raised no concerns, no serious event was attributed to the cells, and there were no increases in falls, fractures, or hospitalizations.

Two participants died during the study, one on treatment and one on placebo, with neither judged related to the infusion.

The cautions deserve equal airtime. The six-month primary endpoint missed significance, the top dose group held only 16 people, and women were underrepresented at the highest doses.

The trial also excluded people with dementia and did not assess cognition, so the effect measured here is mobility, not frailty as a whole.

The funding structure deserves a clear eye. The study was paid for by an NIH grant awarded directly to Longevity, the small company developing the therapy, and the author list includes company employees.

The senior author is that company's chief science officer, and the University of Miami holds equity in it. That does not invalidate the data, but it explains the enthusiasm around them.

You cannot get this infusion today. It is not approved anywhere, and reaching patients would take a larger confirmatory trial.

Why Should You Care?
Frailty has moved from a one-way decline to something medicine can plausibly treat, and this trial is the clearest sign yet of what that could look like.

1. Ruiz JG, Oliva AA Jr, Ramdas KN, Javier J, Rosen J, et al. "Randomized Phase 2b Dose-Escalation Trial of Stem Cell Therapy with Laromestrocel for Aging Frailty." Cell Stem Cell 33(3):393-404, February 25, 2026. DOI 10.1016/j.stem.2026.01.017. Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC13035327/

2. "Stunning new treatment may reverse frailty after just one dose." BBC Science Focus, March 10, 2026. https://www.sciencefocus.com/news/stem-cell-reverse-frailty